Photo from wikipedia
Tofogliflozin is a sodium–glucose cotransporter 2 (SGLT2) inhibitor that lowers plasma glucose levels by enhancing urinary glucose excretion. After its approval in Japan in 2014 for the treatment of type… Click to show full abstract
Tofogliflozin is a sodium–glucose cotransporter 2 (SGLT2) inhibitor that lowers plasma glucose levels by enhancing urinary glucose excretion. After its approval in Japan in 2014 for the treatment of type 2 diabetes mellitus, we carried out a 3‐year prospective observational post‐marketing surveillance study in Japanese patients (Japanese Study of Tofogliflozin with Type 2 Diabetes Mellitus Patients/Long Term [J‐STEP/LT]).
Keywords:
japanese patients;
surveillance study;
type diabetes;
diabetes mellitus;
post marketing;
marketing surveillance
Journal Title: Journal of Diabetes Investigation
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Diabetes Investigation
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!